Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Sold by Marshall Wace LLP

Marshall Wace LLP lessened its holdings in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 27.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,534,378 shares of the company's stock after selling 950,554 shares during the period. Marshall Wace LLP owned 1.12% of Gossamer Bio worth $2,281,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Monaco Asset Management SAM grew its position in shares of Gossamer Bio by 39.5% in the fourth quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock valued at $4,859,000 after purchasing an additional 1,520,721 shares in the last quarter. Geode Capital Management LLC grew its holdings in Gossamer Bio by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company's stock valued at $2,037,000 after buying an additional 38,084 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Gossamer Bio by 1.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company's stock worth $1,123,000 after acquiring an additional 13,902 shares during the period. Finally, Smith Moore & CO. boosted its position in shares of Gossamer Bio by 32.7% during the 4th quarter. Smith Moore & CO. now owns 300,000 shares of the company's stock valued at $271,000 after acquiring an additional 74,000 shares during the last quarter. Institutional investors and hedge funds own 81.23% of the company's stock.

Gossamer Bio Trading Up 6.1 %

GOSS traded up $0.07 on Friday, hitting $1.13. The company had a trading volume of 585,930 shares, compared to its average volume of 1,580,267. The company's fifty day moving average price is $1.07 and its 200 day moving average price is $0.98. Gossamer Bio, Inc. has a 1 year low of $0.50 and a 1 year high of $1.55. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The firm has a market cap of $255.62 million, a P/E ratio of -3.52 and a beta of 1.88.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). The company had revenue of $9.38 million during the quarter, compared to analyst estimates of $7.02 million. As a group, equities analysts expect that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on GOSS. The Goldman Sachs Group cut their price objective on shares of Gossamer Bio from $8.00 to $7.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. Wedbush restated an "outperform" rating and set a $4.00 price target on shares of Gossamer Bio in a report on Friday, March 14th. Finally, HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Gossamer Bio in a report on Tuesday, March 18th.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.